Aegerion Admits to Violating REMS, Pushing Product to Unapproved Populations

Drug Industry Daily
A A
Aegerion Pharmaceuticals pleaded guilty to two criminal misdemeanor violations of the FD&C Act, for failing to comply with REMS requirements for its Juxtapid (lomitapide) cholesterol therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily